<p><strong>Mangoceuticals Inc.</strong> (NASDAQ: MGRX) 的股票在週一大幅上漲。然而，沒有新聞可以解釋這一波動。</p>
<p>這種勢頭可能與上週宣佈的針對其前技術合作夥伴 <strong>Clarity Ventures</strong> 的訴訟有關，該訴訟尋求超過 7300 萬美元的賠償。</p>
<h2>訴訟詳情</h2>
<p>該訴訟在德克薩斯州州法院提起，指控 Clarity 未能交付一個完全功能的、符合 HIPAA 標準的企業資源規劃和電子商務平台，這對 Mangoceuticals 的運營至關重要。</p>
<p>Clarity 否認這些指控，並就未支付的發票提出反訴，Mangoceuticals 認為這些反訴是沒有根據的，因為在解除合作之前已支付所有必要款項。</p>
<h2>向內部平台的轉變增強了 Mangoceuticals 的運營</h2>
<p>針對與 Clarity 的問題，該公司獨立開發了一個新的專有 遠程醫療和電子商務平台，管理層認為這改善了客户獲取和訂單履行。</p>
<p>這一戰略轉變突顯了 Mangoceuticals 在持續訴訟中增強運營表現的承諾。</p>
<p>在投訴中描述的事件之後，Mangoceuticals 表示它獨立開發並部署了一個新的專有遠程醫療和電子商務平台，以支持其運營。</p>
<p>該公司的當前平台是內部開發的，不依賴於 Clarity 的技術。</p>
<h2>Mangoceuticals TRT 計劃憑藉強勁的銷售增長獲得關注</h2>
<p>在二月份，Mangoceuticals 以 <strong>MangoRx</strong> 品牌銷售男性健康產品，報告了其每月 99 美元的注射睾酮 替代療法 (TRT) 計劃 的勢頭。</p>
<p>自去年 12 月中旬推出以來，注射 TRT 計劃的月銷售額增長了 336%，而客户獲取成本下降了 54%，公司在更新中表示。</p>
<p>管理層 預計 TRT 將成為 MangoRx 擴展注射和口服選項（包括由 Kyzatrex 提供支持的 PRIME 膠囊）的主要增長驅動力。</p>
<p>在三月份，Mangoceuticals 提交了一項專利合作條約 (PCT) 國際申請，以確保對驅動 MGX-0024 的抗病毒動物飼料和飲用水添加劑 技術 的廣泛全球專利保護。</p>
<p><strong>MGRX 股票價格活動：</strong> 根據 Benzinga Pro 數據，Mangoceuticals 的股票在週一發佈時上漲了 109.51%，達到 0.34 美元。</p>
<p><em>圖片來源於 Shutterstock</em></p>

醫療業 ETF - SPDR

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Mangoceuticals Inc.（納斯達克代碼：MGRX）股票翻倍，上漲了 109.51%，達到 0.34 美元，儘管沒有新的消息。這一激增是由於對前合作伙伴 Clarity Ventures 提起的訴訟，索賠超過 7300 萬美元，指控其未能交付功能性平台。Clarity 則以未支付發票為由進行反訴。作為回應，Mangoceuticals 開發了自己的遠程醫療和電子商務平台，提升了運營。此外，該公司的睾酮替代療法（TRT）項目自推出以來銷售增長了 336%，管理層預計這將推動未來的增長</p>

<p><strong>Mangoceuticals Inc.</strong> (NASDAQ: MGRX) shares are surging on Monday. However, there is no news to justify the movement.</p>
<div class="lb-trans"><p><strong>Mangoceuticals Inc.</strong> (NASDAQ: MGRX) 的股票在週一大幅上漲。然而，沒有新聞可以解釋這一波動。</p>
</div><p>The momentum could be due to last week’s announcement of a lawsuit seeking damages exceeding 73 million dollars against its former technology partner, <strong>Clarity Ventures</strong>.</p>
<div class="lb-trans"><p>這種勢頭可能與上週宣佈的針對其前技術合作夥伴 <strong>Clarity Ventures</strong> 的訴訟有關，該訴訟尋求超過 7300 萬美元的賠償。</p>
</div><h2>Lawsuit Details</h2>
<div class="lb-trans"><h2>訴訟詳情</h2>
</div><p>The lawsuit, filed in Texas state court, alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource planning and eCommerce platform, which was crucial for Mangoceuticals’ operations.</p>
<div class="lb-trans"><p>該訴訟在德克薩斯州州法院提起，指控 Clarity 未能交付一個完全功能的、符合 HIPAA 標準的企業資源規劃和電子商務平台，這對 Mangoceuticals 的運營至關重要。</p>
</div><p>Clarity has denied these allegations and filed counterclaims regarding unpaid invoices, which Mangoceuticals asserts are unwarranted as all required payments were made before disengagement.</p>
<div class="lb-trans"><p>Clarity 否認這些指控，並就未支付的發票提出反訴，Mangoceuticals 認為這些反訴是沒有根據的，因為在解除合作之前已支付所有必要款項。</p>
</div><h2>Shift To In-House Platform Strengthens Mangoceuticals Operations</h2>
<div class="lb-trans"><h2>向內部平台的轉變增強了 Mangoceuticals 的運營</h2>
</div><p>In response to the issues with Clarity, the company has independently developed a new proprietary telehealth and eCommerce platform, which management believes has improved customer acquisition and order fulfillment.</p>
<div class="lb-trans"><p>針對與 Clarity 的問題，該公司獨立開發了一個新的專有 遠程醫療和電子商務平台，管理層認為這改善了客户獲取和訂單履行。</p>
</div><p>This strategic pivot highlights Mangoceuticals’ commitment to enhancing its operational performance despite ongoing litigation.</p>
<div class="lb-trans"><p>這一戰略轉變突顯了 Mangoceuticals 在持續訴訟中增強運營表現的承諾。</p>
</div><p>Following the events described in the complaint, Mangoceuticals said it independently developed and deployed a new proprietary telehealth and e-commerce platform designed to support its operations.</p>
<div class="lb-trans"><p>在投訴中描述的事件之後，Mangoceuticals 表示它獨立開發並部署了一個新的專有遠程醫療和電子商務平台，以支持其運營。</p>
</div><p>The company’s current platform was developed internally and does not rely on Clarity’s technology.</p>
<div class="lb-trans"><p>該公司的當前平台是內部開發的，不依賴於 Clarity 的技術。</p>
</div><h2>Mangoceuticals TRT Program Gains Traction With Strong Sales Growth</h2>
<div class="lb-trans"><h2>Mangoceuticals TRT 計劃憑藉強勁的銷售增長獲得關注</h2>
</div><p>In February, Mangoceuticals, which sells men’s health products under the <strong>MangoRx</strong> brand, reported momentum for its $99-per-month injectable testosterone replacement therapy (TRT) program.</p>
<div class="lb-trans"><p>在二月份，Mangoceuticals 以 <strong>MangoRx</strong> 品牌銷售男性健康產品，報告了其每月 99 美元的注射睾酮 替代療法 (TRT) 計劃 的勢頭。</p>
</div><p>Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update.</p>
<div class="lb-trans"><p>自去年 12 月中旬推出以來，注射 TRT 計劃的月銷售額增長了 336%，而客户獲取成本下降了 54%，公司在更新中表示。</p>
</div><p>Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.</p>
<div class="lb-trans"><p>管理層 預計 TRT 將成為 MangoRx 擴展注射和口服選項（包括由 Kyzatrex 提供支持的 PRIME 膠囊）的主要增長驅動力。</p>
</div><p>In March, Mangoceuticals filed a Patent Cooperation Treaty (PCT) international application to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.</p>
<div class="lb-trans"><p>在三月份，Mangoceuticals 提交了一項專利合作條約 (PCT) 國際申請，以確保對驅動 MGX-0024 的抗病毒動物飼料和飲用水添加劑 技術 的廣泛全球專利保護。</p>
</div><p><strong>MGRX Stock Price Activity:</strong> Mangoceuticals shares were up 109.51% at $0.34 at the time of publication on Monday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>MGRX 股票價格活動：</strong> 根據 Benzinga Pro 數據，Mangoceuticals 的股票在週一發佈時上漲了 109.51%，達到 0.34 美元。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源於 Shutterstock</em></p>
</div>

Mangoceuticals 的股票在德克薩斯州訴訟後翻了一番